Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Yera Alos, Isis B ^a   Alonso Carbonell, Liuba ^a   Valenzuela Silva, Carmen M ^b   Tuero Iglesias, Angela D ^b   Moreira Martínez, Martha ^c   Marrero Rodríguez, Ivonne ^d   López Mola, Ernesto ^b   López Saura, Pedro A ^b  

^a Center for Development of Pharmacoepidemiology (CDF)   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c Abel Santamaría Hospital   (Cuba)

^d Gustavo Aldereguia Hospital   (Cuba)

Author keywords

Diabetic foot ulcer; Epidermal growth factor; Pharmacoepidemiology

Indexed keywords

HEBERPROT P; RECOMBINANT EPIDERMAL GROWTH FACTOR; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; BURNING SENSATION; CHILL; CONSCIOUSNESS DISORDER; DIABETIC FOOT; DIABETIC KETOACIDOSIS; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENTEROCOLITIS; FAINTNESS; FEMALE; FEVER; FOLLOW UP; FOOT AMPUTATION; FOOT PAIN; GRANULATION TISSUE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MULTICENTER STUDY; MUSCLE SPASM; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RELAPSE; SEPTIC SHOCK; SHIVERING; SKIN INFECTION; SUDDEN CARDIAC DEATH; VOMITING; WOUND CARE; AMPUTATION; DOSE RESPONSE; DRUG EFFECT; INTRALESIONAL DRUG ADMINISTRATION; MIDDLE AGED; POSTMARKETING SURVEILLANCE; STATISTICS; TREATMENT OUTCOME; VERY ELDERLY; WOUND HEALING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMPUTATION; DIABETIC FOOT; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; FEMALE; GRANULATION TISSUE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 84884334141     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-44     Document Type: Article

References (44)

1. Armstrong DG, Cohen K, Courric S, Bharara M, Marston W. Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Technol 2011, 5:1591-1595. 3262731, 22226282.
2. Berlanga J. Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment. Int Wound J 2011, 8:612-620. 10.1111/j.1742-481X.2011.00840.x, 21910827.
3. López-Saura PA, Berlanga-Acosta J, Fernández-Montequín JI, Valenzuela-Silva C, González-Díaz O, Savigne W, Morejon-Vega L, Del Río-Martín A, Herrera-Martínez L, López-Mola E, Acevedo-Castro B. Intralesional human recombinant epidermal growth factor for the treatment of advanced diabetic foot ulcer: from proof of concept to confirmation of the efficacy and safety of the procedure. Global perspective on diabetic foot ulcerations 2011, 217-238. Rijeka: InTech Europe, Dihn T, http://www.intechopen.com/articles/show/title/intralesional-human-recombinant-epidermal-growth-factor-for-the-treatment-of-advanced-diabetic-foot-.
4. Berlanga J, Savigne W, Valdez C, Franco N, Alba JS, Del Rio A, López-Saura P, Guillén G, Lopez E, Herrera L, Férnandez-Montequín J. Epidermal growth factor intra-lesional can prevent amputation in diabetic patients with advanced foot wounds. Int Wound J 2006, 3:232-239. 10.1111/j.1742-481X.2006.00237.x, 16984579.
5. Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutierrez W, Artaza-Sanz H, Morejón-Vega L, González-Benavides C, Eliseo-Musenden O, García-Iglesias E, Berlanga-Acosta J, Silva-Rodríguez R, Betancourt BY, López-Saura PA, Cuban Citoprot-P Study Group Intralesional injections of Citoprot P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J 2007, 4:333-343. Cuban Citoprot-P Study Group.
6. Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, López Mola E, Galán-Naranjo K, Ramírez-Navas M, Bermúdez-Rojas S, Rosales F, García-Iglesias E, Berlanga-Acosta J, Silva-Rodriguez R, Garcia-Siverio M, Herrera Martinez L. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in advanced diabetic foot ulcer: treatment up to complete wound closure. Int Wound J 2009, 6:67-72. 10.1111/j.1742-481X.2008.00561.x, 19291119.
7. Fernández-Montequín JI, Valenzuela-Silva CM, González-Díaz O, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, Sánchez-Penton P, Morejón-Vega L, Artaza-Sanz H, García-Herrera A, González-Benavides C, Hernández-Cañete CM, Vázquez-Proenza A, Berlanga-Acosta J, López-Saura PA, for the Cuban Diabetic Foot Study Group Intralesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers. Multicenter, randomized, placebo-controlled, double blind study. Int Wound J 2009, 6:432-443. 10.1111/j.1742-481X.2009.00641.x, 20051095, for the Cuban Diabetic Foot Study Group.
8. Armstrong DG, Lavry LA, Harkless LB. Validation of a diabetic wound classification system: the contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998, 21:855-859. 10.2337/diacare.21.5.855, 9589255.
9. The Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring WHO Adverse reaction terminology 2008 2008, Uppsala: UMC, Available from http://www.umc-products.com/DynPage.aspx?id=73589&mn1=1107&mn2=1664, The Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring.
10. Edwards RI, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994, 10:93-102. 10.2165/00002018-199410020-00001, 8011183.
11. National Report of the Population and Housing Census of Cuba 2002 2002, La Habana: Bureau for Statistics, Available from: http://www.cubagob.cu/otras_info/censo/tablas_html/ii_3.htm; accessed on 06/23/2012, National Report of the Population and Housing Census of Cuba 2002.
12. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, Van Baal J, Van Merode F, Schaper N. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007, 50:18-25.
13. Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics 2008, 2:1-12. 2727777, 19707423.
14. Chipchase SY, Treece KA, Pound N, Game FL, Jeffcoate WJ. Heel ulcers don't heal in diabetes. Or do they?. Diabet Med 2005, 22:1258-1262. 10.1111/j.1464-5491.2005.01665.x, 16108858.
15. Smith DI, Swamy PM, Heffernan MP. Off-label uses of biologics in dermatology: Interferon and intravenous immunoglobulin (Part 1 of 2). J Am Acad Dermatol 2007, 56(Suppl 1):e1-e54.
16. Graves JE, Nunle K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). J Am Acad Dermatol 2007, 56(Suppl 1):e55-e79.
17. Valenzuela-Silva CM, Tuero-Iglesias AD, García-Iglesias E, González-Díaz O, Del Río-Martín A, Year-Alos IB, Fernández-Montequín JI, López-Saura PA. Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant, human epidermal growth factor. Diabetes Care 2013, 36:210-215. 10.2337/dc12-1323, 22966096.
18. Matricali GA, Deroo K, Dereymaeker G. Outcome and recurrence rate of diabetic foot ulcers treated by a total contact cast: short-term follow-up. Foot Ankle Int 2003, 24:680-684.
19. Frigg A, Pagenstert G, Schäfer D, Valderrabano V, Hintermann B. Recurrence and prevention of diabetic foot ulcers after total contact casting. Foot Ankle Int 2007, 28:64-69. 10.3113/FAI.2007.0012, 17257541.
20. Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005, 366:1719-1724. 10.1016/S0140-6736(05)67698-2, 16291066.
21. Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EYN, Kam G, Leung L, Chan CW, Chu CM, Lam EKH. Human epidermal growth. Factor enhances healing of diabetic foot ulcers. Diabetes Care 2003, 26:1851-1856.
22. Viswanathan V, Pendsey S. A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D™ 150) in healing diabetic foot ulcers. Wounds 2006, 18:186-196.
23. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor- B (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998, 21:822-827. 10.2337/diacare.21.5.822, 9589248.
24. Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, Tamaki K, Hirakata H, Ohura T, Furue M. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol 2009, 19:461-468.
25. Papanas N, Maltezos E. Benefit-Risk Assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf 2010, 33:455-461. 10.2165/11534570-000000000-00000, 20486728, Benefit-Risk.
26. Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, Uccioli L, Urbancic V, Bakker K, Holstein P, Jirkovska A, Piaggesi A, Ragnarson-Tennvall G, Reike H, Spraul M, Van Acker K, Van Baal J, Van Merode F, Ferreira I, Huijberts M. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 2008, 51:747-755. 10.1007/s00125-008-0940-0, 2292424, 18297261.
27. Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV. Diabetic foot disorders: a clinical practice guideline (2006 revision). J Foot Ankle Surg 2006, 45(Suppl 5):S1-S66.
28. Verdú J, Marinel-lo J, Armans E, Carreño P, March JR, Soldevilla J. National conference for consensus on low extremity ulcers 2009, Spain: EdikaMed S.L, (in Spanish).
29. Snyder RJ, Kirsner RS, Warriner RA, Lavery LA, Hanft JR, Sheehan P. Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage 2010, 56(4 Suppl):S1-S24.
30. González-Acosta S, Calaña-González-Posada B, Marrero-Rodríguez I, López-Fernández R. Clinical evolution of diabetic foot treatment with Heberprot-P or with the conventional method. Rev Cubana Angiología y Cirugía Vascular 2011, 11(2):11. (in Spanish). Available from http://bvs.sld.cu/revistas/ang/vol_11_2_11/ang07211.htm.
31. García Herrera AL, Rodríguez Fernández R, Ruiz VM, Rodríguez Hernández L, Acosta Cabadilla L, Febles Sanabria R, Pancorbo Sandoval C, Cantero Calderón S, Vázquez Díaz O, Moliner Cartaya M. Reduction in the amputation rate with Heberprot P in the local treatment of diabetic foot. Spanish Journal of Surgical Research 2011, XIV:21-26. (in Spanish).
32. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004, 39(Suppl 2):S104-S114.
33. Iversen MM, Tell GS, Riise T, Hanestad BR, Østbye T, Graue M, Midthjell K. History of foot ulcer increases mortality among individuals with diabetes: ten-year follow-up of the Nord-Trøndelag health study, Norway. Diabetes Care 2009, 32:2193-2199. 10.2337/dc09-0651, 2782976, 19729524.
34. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011, 171:404-410. 10.1001/archinternmed.2011.2, 21403036.
35. Ministry of Public Health Cuban health yearbook 2011 2012, La Habana, Available from: http://files.sld.cu/bvscuba/files/2012/05/anuario-2011-e.pdf, Ministry of Public Health.
36. Brownrigg JRW, Davey J, Holt PJ, Davis WA, Thompson MM, Ray KK, Hinchliffe RJ. The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis. Diabetologia 2012, 55:2906-2912. 10.1007/s00125-012-2673-3, 22890823.
37. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012, 35:1835-1844. 10.2337/dc12-0002, 3425000, 22699290.
38. Berlanga-Acosta J, Gavilondo-Cowley J, García del Barco-Herrera D, Martín-Machado J, Guillen-Nieto G. Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as tissue healing agents: clarifying concerns about their possible role in malignant transformation and tumor progression. J Carcinogene Mutagene 2011, 2:1.
39. Berlanga-Acosta J, Gavilondo-Cowley J, López-Saura P, González-López T, Castro-Santana MD, López-Mola E, Guillén-Nieto G, Herrera-Martinez L. Epidermal Growth Factor (EGF) in clinical practice-a review of its biological actions, clinical indications and safety implications. Int Wound J 2009, 6:331-346. 10.1111/j.1742-481X.2009.00622.x, 19912390.
40. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Postoperative mortality in cancer patients with preexisting diabetes. Diabetes Care 2010, 33:931-939. 10.2337/dc09-1721, 2845055, 20351229.
41. Hense HW, Kajüter H, Wellmann J, Batzler WU. Cancer incidence in type 2 diabetes patients -first results from a feasibility study of the D2C cohort. Diabetol Metabol Syndrome 2011, 3:15.
42. Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, DeCamp MM. Factors associated with local and distant recurrence and survival in patients with resected non-small cell lung cancer. Cancer 2009, 115:1059-1069. 10.1002/cncr.24133, 19152440.
43. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control 2012, 23:967-981. 10.1007/s10552-012-9972-3, 22552844.
44. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer. A consensus report. Diabetes Care 2010, 33:1674-1685. 10.2337/dc10-0666, 2890380, 20587728.